This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Taisho Pharmaceutical Co., Ltd.

Drug Names(s): Parogrelil, NM-702, INDI-702

Description: NT-702 is a selective phosphodiesterase (PDE) 3 and thromboxane synthetase inhibitor.

Deal Structure: In September 2002, Taisho signed an agreement with Nissan Chemical for the joint development of NT-702.

In May 2007, Nissan and Taisho signed a licensing agreement for NM-702 with Milford Sound Sciences. Under this agreement, Nissan and Taisho granted Milford exclusive development and marketing rights worldwide, except in Japan, South Korea, China and Taiwan. In return, Milford will make a one-off payment on the execution of the license followed by milestone payments based on the development progress and royalty payments based on sales. Milford later became known as Indigo Pharmaceuticals, and as of September 2010, it appears to no longer be a going concern.

Partners: Nissan Chemical Industries Ltd.

NT-702 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug